dc.contributor.author | RYDER, SHEILA | en |
dc.contributor.author | WALSH, JOHN | en |
dc.date.accessioned | 2013-09-03T10:41:48Z | |
dc.date.available | 2013-09-03T10:41:48Z | |
dc.date.issued | 2013 | en |
dc.date.submitted | 2013 | en |
dc.identifier.citation | Prokopiou EM, Ryder SA, Walsh JJ, Tumour vasculature targeting agents in hybrid/conjugate drugs., Angiogenesis, 16, 3, 2013, 503 - 524 | en |
dc.identifier.issn | 0969-6970 | en |
dc.identifier.other | Y | en |
dc.identifier.uri | http://hdl.handle.net/2262/67312 | |
dc.description | PUBLISHED | en |
dc.description | PMID: 23543223 | en |
dc.description.abstract | Tumour vasculature targeting has been a very active area of cancer drug discovery over the last decade. Growth of solid tumours beyond a certain point requires a sufficient blood supply in order for them to develop and metastasise. While novel anti-angiogenic and vascular disrupting agents represent an important contribution to the armoury of anti-cancer agents, they nevertheless usually require combination with standard cytotoxic therapy in order to demonstrate positive clinical outcomes. In line with this consensus, a new concept has arisen, namely the design of functional hybrids where at least one component of the design targets a tumour angiogenic/vasculature pathway. This review will outline examples of such hybrid/conjugate-based approaches. Emphasis will be placed on their preclinical evaluation with particular focus on the arginine-glycine-aspartic acid/asparagine-glycine-arginine (RGD/NGR) conjugates, heparin-related hybrids and antibody-drug conjugates. In conclusion, the benefits and shortcomings of hybrids under development will be discussed in the context of future directions and applications. | en |
dc.format.extent | 503 | en |
dc.format.extent | 524 | en |
dc.language.iso | en | en |
dc.relation.ispartofseries | Angiogenesis | en |
dc.relation.ispartofseries | 16 | en |
dc.relation.ispartofseries | 3 | en |
dc.rights | Y | en |
dc.subject | Angiogenesis | en |
dc.subject | Combination therapy | en |
dc.subject | Conjugates | en |
dc.subject | Hybrids | en |
dc.subject | Tumour vasculature | en |
dc.subject | Vascular disrupting agents | en |
dc.subject.lcsh | Neovascularization | en |
dc.subject.lcsh | Neovascularization inhibitors | en |
dc.subject.lcsh | Chemotherapy, Combination | en |
dc.subject.lcsh | Conjugation chemistry | en |
dc.subject.lcsh | Cancer | en |
dc.subject.lcsh | Blood-vessels | en |
dc.title | Tumour vasculature targeting agents in hybrid/conjugate drugs. | en |
dc.type | Journal Article | en |
dc.type.supercollection | scholarly_publications | en |
dc.type.supercollection | refereed_publications | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/sryder | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/jjwalsh | en |
dc.identifier.rssinternalid | 85410 | en |
dc.identifier.doi | http://dx.doi.org/10.1007/s10456-013-9347-8 | en |
dc.subject.TCDTheme | Cancer | en |
dc.identifier.rssuri | http://link.springer.com/article/10.1007%2Fs10456-013-9347-8 | en |
dc.identifier.rssuri | http://rdcu.be/C7pf | en |
dc.identifier.rssuri | http://www.ncbi.nlm.nih.gov/pubmed/23543223 | en |